A new interactive resource to facilitate the delivery of holistic care.Thi
In this article, the authors review evidence, guidance and current practice to provide a consensus approach to calculating and interpreting peak expiratory flow rate (PEFR) variability and reversibility from peak flow diary recordings for asthma diagnosis.
In this article the authors review current evidence and guidance for the treatment of Chronic obstructive pulmonary disease (COPD) in order to bring up to date the Primary Care Respiratory Society (PCRS) consensus approach and algorithm first published in 2017 known as ‘Keeping it Simple’.
In 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of a dual (Inhaled corticosteroid/ Formoterol) combination treatment to be used as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an a
NICE Diagnostic Guidance 12 (DG12); Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath.
NICE guidance is integral to the clinical care that we offer as Health Care Professionals (HCPs).
accuRx has created a FeNO template to send to patients prior to their appointment via text message. For information on what's included and how to find the template, have a look at the guidance document below.
This may include an understanding of the benefits of having a FeNO test, including:
These templates are only available to EMIS and TPP users – they are not available to MicroTest and Vision users.
The AHSN Network supported the spread of FeNO testing across primary care in England from April 2021 to March 2023, led by Wessex AHSN as the lead AHSN. This programme was delivered as part of the NHS England Accelerated Access Collaborative Rapid Uptake Programme.
The one-minute sit to stand test (1-MSTST) has become the test of choice during the pandemic for measuring exercise capacity, both at in-person and virtual appointments due to the inability to conduct robust six minute or incremental / endurance shuttle walk tests (6MWT/ ISWT/ ESWT).
Non-tuberculous mycobacteria (NTM) are a group of bacteria that are capable of causing opportunistic lung infections and the development of NTM pulmonary disease (NTM-PD).
In this article we review the major changes in the 2023 GOLD report as they impact on the initial and ongoing pharmacological management of COPD and consider the implications for primary care in the UK.
This pragmatic guide on the identification, referral and ongoing management of adults and children with severe asthma has been developed by an expert group led by Dr Steve Holmes, a GP based in Shepton Mallet, Somerset and including Will Carroll, University Hospital of the North Midlands, Stoke-o
Historically, clinical decision rules have been used to guide antibiotic prescribing for patients presenting with signs and symptoms that indicate possible RTIs or infectious exacerbations of chronic obstructive pulmonary disease (IE-COPD).